vs
费森尤斯医疗（FMS）与MANGOCEUTICALS, INC.（MGRX）财务数据对比。点击上方公司名可切换其他公司
费森尤斯医疗的季度营收约是MANGOCEUTICALS, INC.的58024.1倍（$5.5B vs $94.4K）。费森尤斯医疗净利率更高（7.9% vs -2935.1%，领先2943.0%）。费森尤斯医疗同比增速更快（-0.3% vs -10.3%）
费森尤斯医疗是德国知名医疗保健企业，核心业务为肾脏透析服务，在全球运营4171家门诊透析中心，服务约34.54万名患者。公司主要为终末期肾病患者提供治疗服务，该类患者需终身每周接受3次透析治疗以维持生命。
MANGOCEUTICALS INC是一家专注男士健康护理的企业，研发销售经科学验证的膳食补充剂、男士护肤及护发产品，主要面向美国市场，通过直营电商平台及精选零售渠道为成年男性提供便捷透明的健康护理解决方案。
FMS vs MGRX — 直观对比
营收规模更大
FMS
是对方的58024.1倍
$94.4K
营收增速更快
FMS
高出10.0%
-10.3%
净利率更高
FMS
高出2943.0%
-2935.1%
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $5.5B | $94.4K |
| 净利润 | $434.2M | $-2.8M |
| 毛利率 | 27.4% | 50.3% |
| 营业利润率 | 11.7% | -389.7% |
| 净利率 | 7.9% | -2935.1% |
| 营收同比 | -0.3% | -10.3% |
| 净利润同比 | 240.4% | -42.1% |
| 每股收益（稀释后） | — | $0.38 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收FMSMGRX
| Q4 25 | $5.5B | $94.4K | ||
| Q3 25 | — | $84.2K | ||
| Q2 25 | — | $168.1K | ||
| Q1 25 | — | $109.3K | ||
| Q4 24 | $5.5B | $105.2K | ||
| Q3 24 | — | $133.4K | ||
| Q2 24 | — | $163.2K | ||
| Q1 24 | — | $214.1K |
净利润FMSMGRX
| Q4 25 | $434.2M | $-2.8M | ||
| Q3 25 | — | $-7.6M | ||
| Q2 25 | — | $-5.4M | ||
| Q1 25 | — | $-4.8M | ||
| Q4 24 | $127.6M | $-1.9M | ||
| Q3 24 | — | $-2.0M | ||
| Q2 24 | — | $-2.4M | ||
| Q1 24 | — | $-2.4M |
毛利率FMSMGRX
| Q4 25 | 27.4% | 50.3% | ||
| Q3 25 | — | 60.4% | ||
| Q2 25 | — | 53.5% | ||
| Q1 25 | — | 56.8% | ||
| Q4 24 | 25.0% | 76.1% | ||
| Q3 24 | — | 62.0% | ||
| Q2 24 | — | 42.8% | ||
| Q1 24 | — | 68.8% |
营业利润率FMSMGRX
| Q4 25 | 11.7% | -389.7% | ||
| Q3 25 | — | -8953.5% | ||
| Q2 25 | — | -3134.0% | ||
| Q1 25 | — | -4440.0% | ||
| Q4 24 | 5.1% | -1594.0% | ||
| Q3 24 | — | -1318.2% | ||
| Q2 24 | — | -1329.1% | ||
| Q1 24 | — | -1105.9% |
净利率FMSMGRX
| Q4 25 | 7.9% | -2935.1% | ||
| Q3 25 | — | -9042.8% | ||
| Q2 25 | — | -3221.6% | ||
| Q1 25 | — | -4427.4% | ||
| Q4 24 | 2.3% | -1851.2% | ||
| Q3 24 | — | -1499.0% | ||
| Q2 24 | — | -1465.4% | ||
| Q1 24 | — | -1105.9% |
每股收益（稀释后）FMSMGRX
| Q4 25 | — | $0.38 | ||
| Q3 25 | — | $-0.69 | ||
| Q2 25 | — | $-0.57 | ||
| Q1 25 | — | $-1.29 | ||
| Q4 24 | — | $-0.79 | ||
| Q3 24 | — | $-1.14 | ||
| Q2 24 | — | $-1.37 | ||
| Q1 24 | — | $-1.50 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $1.7B | $1.5M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $15.4B | $15.2M |
| 总资产 | $33.5B | $16.1M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资FMSMGRX
| Q4 25 | $1.7B | $1.5M | ||
| Q3 25 | — | $481.3K | ||
| Q2 25 | — | $101.0K | ||
| Q1 25 | — | $76.5K | ||
| Q4 24 | $1.3B | $58.7K | ||
| Q3 24 | — | $73.9K | ||
| Q2 24 | — | $490.2K | ||
| Q1 24 | — | $15.3K |
股东权益FMSMGRX
| Q4 25 | $15.4B | $15.2M | ||
| Q3 25 | — | $15.7M | ||
| Q2 25 | — | $19.2M | ||
| Q1 25 | — | $20.3M | ||
| Q4 24 | $17.0B | $13.9M | ||
| Q3 24 | — | $13.4M | ||
| Q2 24 | — | $13.8M | ||
| Q1 24 | — | $-958.4K |
总资产FMSMGRX
| Q4 25 | $33.5B | $16.1M | ||
| Q3 25 | — | $16.5M | ||
| Q2 25 | — | $20.8M | ||
| Q1 25 | — | $21.8M | ||
| Q4 24 | $36.3B | $15.4M | ||
| Q3 24 | — | $14.8M | ||
| Q2 24 | — | $15.2M | ||
| Q1 24 | — | $301.4K |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $2.9B | $-1.1M |
| 自由现金流经营现金流 - 资本支出 | — | — |
| 自由现金流率自由现金流/营收 | — | — |
| 资本支出强度资本支出/营收 | — | — |
| 现金转化率经营现金流/净利润 | 6.67× | — |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流FMSMGRX
| Q4 25 | $2.9B | $-1.1M | ||
| Q3 25 | — | $-1.2M | ||
| Q2 25 | — | $-1.3M | ||
| Q1 25 | — | $-2.3M | ||
| Q4 24 | $2.6B | $-1.1M | ||
| Q3 24 | — | $-1.2M | ||
| Q2 24 | — | $-1.6M | ||
| Q1 24 | — | $-991.1K |
现金转化率FMSMGRX
| Q4 25 | 6.67× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 20.20× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
